$Clovis肿瘤药物(CLVS)$ Phase 3 ARIEL4 study of Rubraca met its primary endpoint, showing a statistically significant improvement in progression-free survival for Rubraca versus chemotherapy in ovarian cancer.
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$Clovis肿瘤药物(CLVS)$ Phase 3 ARIEL4 study of Rubraca met its primary endpoint, showing a statistically significant improvement in progression-free survival for Rubraca versus chemotherapy in ovarian cancer.